Chinese biotech company Vigonvita Life Sciences has filed for an initial public offering (IPO) on the Hong Kong Stock ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers.

That Ascentage is the first IPO to complete in the US ties ... In a statement, Ascentage said it is the first pre-revenue biotech company on the Hong Kong Exchange to be dual-listed on the US ...

The biotech is seeking funding for the programs from investors who have plenty of IPOs to pick from. Ab&B is one of eight biotechs that have filed to go public in Hong Kong over the past month and ...

Shenzhen-headquartered electric vehicle battery firm Contemporary Amperex Technology Co., Limited (CATL) has filed an ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

China’s Contemporary Amperex Technology (CATL), the world’s largest producer of batteries for electric vehicles and a supplier for Tesla, has applied for a listing in Hong Kong, setting sights on one ...

Wealth management and family offices will be a major growth engine for Hong Kong, as many prominent clans in Asia have shown an interest in setting up entities to manage their fortunes ...

Takeda paid $100m upfront for the option to licence olverembatinib outside China, Hong Kong, Macau, Taiwan ... "Ascentage Pharma raises $126m in first biotech IPO of 2025" was originally created and ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly ... on The Stock Exchange of Hong Kong since 2019.